Cargando…
Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2
Incubation of resting lymphoid cells with recombinant interleukin 2 (IL- 2) in vitro leads to the generation of lymphokine activated killer (LAK) cells capable of lysing fresh tumor cell suspensions in short- term chromium-release assays. Our previous studies (7) have demonstrated that the injection...
Formato: | Texto |
---|---|
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
1985
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2187617/ https://www.ncbi.nlm.nih.gov/pubmed/3886826 |
Ejemplares similares
-
Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma.
por: Ravaud, A., et al.
Publicado: (1994) -
High-Dose Vitamin C Promotes Regression of Multiple Pulmonary Metastases Originating from Hepatocellular Carcinoma
por: Seo, Min-Seok, et al.
Publicado: (2015) -
Safety of low-dose subcutaneous recombinant interleukin-2: systematic review and meta-analysis of randomized controlled trials
por: Mahmoudpour, Seyed Hamidreza, et al.
Publicado: (2019) -
Tumor Regression upon Intratumoral and Subcutaneous Dosing of the STING Agonist ALG-031048 in Mouse Efficacy Models
por: Jekle, Andreas, et al.
Publicado: (2023) -
Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections--a phase I dose toxicity trial.
por: Gilleece, M. H., et al.
Publicado: (1992)